Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in Rural Chinese patients with essential hypertension

Clinical Therapeutics

Volumn 27, Issue 11, 2005, Pages 1774-1784

  Zhang, Shanchun ^a   Mao, Guangyun ^b   Zhang, Yan ^c   Tang, Genfu ^b   Wen, Yufeng ^b   Hong, Xiumei ^a   Jiang, Shanqun ^a   Yu, Yunxian ^a   Xu, Xiping ^a,b,d  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antihypertensive efficacy; Atrial natriuretic peptide; Chinese; Hypertension; Irbesartan; Polymosphism

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; IRBESARTAN; METHIONINE; VALINE;

ADULT; ALCOHOL CONSUMPTION; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EDUCATION; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATION; PHARMACOGENETICS; PROTEIN FUNCTION; RURAL POPULATION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL NATRIURETIC FACTOR; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHINA; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RURAL POPULATION; TETRAZOLES;

EID: 29144431607     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.11.008     Document Type: Article

References (42)

1. Rowland M., and Roberts J. Blood pressure levels and hypertension in persons ages 6-74 years: United States, 1976-1980 Adv Data 84 1982 1 11
2. Wu Y.K., Lu C.Q., and Gao R.C. Nation-wide hypertension screening in China during 1979-1980 Chin Med J (Engl) 95 1982 101 108
3. [published correction appears in Rev Med Chil. 1990; 118:1041] Berríos X., Jadue L., and Zenteno J. Prevalence of risk factors for chronic diseases. A study in the general population of the metropolitan area, 1986-1987 [in Spanish] Rev Med Chil 118 1990 597 604
4. [published correction appears in N Engl J Med. 1994;330:1689] Materson B.J., Reda D.J., Cushman W.C. Department of Veterans Affairs Cooperative Study Group on Anti hypertensive Agents Single-drug therapy for hypertension in men. A comparison of six anti hypertensive agents with placebo N Engl J Med 328 1993 914 921
5. Wijeyaratne C.N., and Moult P.J. The effect of alpha human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects J Clin Endocrinol Metab 76 1993 343 346
6. Reeves R.A., Lin C.S., Kassler-Taub K., and Pouleur H. Dose-related efficacy of irbesartan for hypertension: An integrated analysis Hypertension 31 1998 1311 1316
7. Pool J.L., Guthrie R.M., and Littlejohn T.W. III Dose-related antihypertensive effects of irbesartan in patients with mild-tomoderate hypertension Am J Hypertens 11 1998 462 470
8. Gillis J.C., and Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension Drugs 54 1997 885 902
9. Croom K.F., Curran M.P., Goa K.L., and Perry C.M. Irbesartan: A review of its use in hypertension and in the management of diabetic nephropathy Drugs 64 2004 999 1028
10. [published correction appears in Pharmacogenetics. 2002 12:343] Lee C.R., Goldstein J.A., and Pieper J.A. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data Pharmacogenetics 12 2002 251 263
11. Babaoglu M.O., Yasar U., and Sandberg M. CYP2C9 genetic variants and losartan oxidation in a Turkish population Eur J Clin Pharmacol 60 2004 337 342
12. Evans W.E., and Relling M.V. Pharmacogenomics: Translating functional genomics into rational therapeutics Science 286 1999 487 491
13. Goodfriend T.L., Elliott M.E., and Catt K.J. Angiotensin receptors and their antagonists N Engl J Med 334 1996 1649 1654
14. Kotridis P., Kokkas B., and Karamouzis M. Plasma atrial natriuretic peptide in essential hypertension after treatment with irbesartan Blood Press 11 2002 91 94
15. Papadopoulos C.L., and Kokkas B.A. Atrial natriuretic peptide contributes to the anti hypertensive action of many drugs EurJ DrugMetab Pharmacokinet 28 2003 55 57
16. Guidelines Subcommittee 1999 World Health OrganizationInternational Society of Hypertension Guidelines for the Management of Hypertension J Hypertens 17 1999 151 183
17. People's Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group An epidemiological study of cardiovascular and cardiopul monary risk factors in four populations in the People's Republic of China. Baseline reportfrom the P.R.C.-U.S.A. Collaborative Study Circulation 85 1992 1083 1096
18. Chang S.Y., Whigan D.B., Vachharajani N.N., and Patel R. High-performance liquid chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine J Chromatogr B Biomed Sci Appl 702 1997 149 155
19. Nkeh B., Tiago A., and Candy G.P. Association between an atrial natriuretic peptide gene polymorphism and normal blood pressure in subjects of African ancestry Cardiovasc J S Afr 13 2002 97 101
20. John S.W., Krege J.H., and Oliver P.M. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension Science 267 1995 679 681
21. Koh G.Y., Klug M.G., and Field L.J. Atrial natriuretic factor and transgenic mice Hypertension 22 1993 634 639
22. Rahmutula D., Nakayama T., and Soma M. Association study between the variants of the human ANP gene and essential hypertension Hypertens Res 24 2001 291 294
23. Nakayama T., Soma M., and Mizutani Y. A novel missense mutation of exon 3 in the type A human natriuretic peptide receptor gene: Possible association with essential hypertension Hypertens Res 25 2002 395 401
24. Nannipieri M., Manganiello M., and Pezzatini A. Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension Hypertension 37 2001 1416 1422
25. Nakayama T., Soma M., and Takahashi Y. Nucleotide sequence of the 5′-flanking region of the type A human natriuretic peptide receptor gene and association analysis using a novel microsatellite in essential hypertension Am J Hypertens 12 1999 1144 1148
26. Cheung B.M., Leung R., and Shiu S. Hpall polymorphism in the atrial natriuretic peptide gene and hypertension Am J Hypertens 12 1999 524 527
27. Barley J., Carter N.D., and Cruickshank J.K. Renin and atrial natriuretic peptide restriction fragment length polymorphisms: Association with ethnicity and blood pressure J Hypertens 9 1991 993 996
28. Dietz J.R., Scott D.Y., Landon C.S., and Nazian S.J. Evidence supporting a physiological role for proANP-(1-30) in the regulation of renal excretion Am J Physiol Regul Integr Comp Physiol 280 2001 R1510 R1517
29. Benjamin B.A., and Peterson T.V. Effect of proANF-(31-67) on sodium excretion in conscious monkeys Am J Physiol 269 1995 R1351 R1355
30. Nakayama K., Ohkubo H., and Hirose T. mRNA sequence for human card iodilatin-atrialnatriuretic factor precursor and regulation of precursor mRNA in rat atria Nature 310 1984 699 701
31. Vesely D.L. Atrial natriuretic hormones originating from the N-terminus of the atrial natriuretic factor prohor mone Clin Exp Pharmacol Physiol 22 1995 108 114
32. Seidman C.E., Bloch K.D., and Klein K.A. Nucleotide sequences of the human and mouse atrial natriuretic factor genes Science 226 1984 1206 1209
33. Rubattu S., Ridker P., and Stampfer M.J. The gene encoding atrial natriuretic peptide and the risk of human stroke Circulation 100 1999 1722 1726
34. Chando T.J., Everett D.W., and Kahle A.D. Biotransformation of irbesartan in man 26 1998 408 417
35. Volpe M., Odell G., and Kleinert H.D. Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension Hypertension 7 1985 143 148
36. Maack T., Marion D.N., and Camargo M.J. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs Am J Med 77 1984 1069 1075
37. Hisa H., Tomura Y., Yamagata T., and Satoh S. Atrial natriuretic peptide renal vasoconstriction induced by angiotensin II and norepinephrine in dogs Eur J Pharmacol 222 1992 265 271
38. Oelkers W., Kleiner S., and Bahr V. Effects of incremental infusions of atrial natriuretic factor on aldosterone, renin, and blood pressure in humans Hypertension 12 1988 462 467
39. Ackermann U., and Azizi N. Increased central AT(1)-receptor activation, not systemic vasopressin, sustains hypertension in ANP knockout mice Am J Physiol Regul Integr Comp Physiol 278 2000 R1441 R1445
40. Kohno M., Yasunari K., and Matsuura T. Circulating atrial natriuretic polypeptide in essential hypertension Am Heart J 113 1987 1160 1163
41. Nakamura T., Ichikawa S., and Sakamaki T. Plasma levels of atrial natriuretic peptide in patients with bor derline and essential hypertension Tohoku J Exp Med 154 1988 205 213
42. Hedner T., Hartford M., and Caidahl K. Atrial natriuretic peptide (ANP) in relation to blood pressure: A study in middle-aged men with normal and elevated blood pressure J Intern Med 225 1989 229 235